LEXX - Lexaria Bioscience Corp. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

LEXX

LEXARIA BIOSCIENCE CORP.

NASDAQ

$10.35

▼ DOWN 11.39% (-1.33)

KEY STATISTICS

Market Cap$17.10 M

52w High$23.25

52w Low$4.21

Dividend Yield—

Frequency—

P/E-1.97

Volume61.91K

Shares Out.1.65M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Richard C. Christopher

COMPENSATION 2026

Salary$96,000

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$0

Total$147,360

ABOUT

SECTOR

Healthcare

WENT PUBLIC

January 12, 2021

METHOD OF GOING PUBLIC

SPAC

FULL TIME EMPLOYEES

PRICE TARGET

Target High$1.50

Target Low$1.50

Target Median$1.50

Target Consensus$1.50

UPCOMING EARNINGS

DateOct 28, 2026

DayWednesday

Rev. Est.$50.00K

OCT

WED

SPLIT RECORD

DATE	TYPE	RATIO
2026-08-03	Reverse	1:15
2021-01-12	Reverse	1:30
2015-12-16	Forward	11:10
2009-06-30	Reverse	1:4

PRICE

$10.35 ▼ DOWN 11.39% (−$1.33)

OVERLAYS

About Lexaria Bioscience Corp.

https://www.lexariabioscience.com ↗

Lexaria Bioscience Corp. is a biotech company with patented DehydraTECH technology that enhances oral drug delivery, increasing absorption, reducing onset time, and crossing the blood-brain barrier for cannabinoids, nicotine, and other pharmaceuti...

INDUSTRY

Biotechnology

A SERVICE LEXARIA BIOSCIENCE CORP. IS KNOWN FOR

DehydraTECH™

DehydraTECH™ is a patented drug delivery platform that enhances oral absorption, speed, and effectiveness of fat-soluble drugs, licensed to companies in pharma, nicotine, and nutraceutical sectors.